Animal Models of Hepatitis C Virus Infection
Patrizia Farci
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
Search for more papers by this authorJens Bukh
Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre; and Department of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
Search for more papers by this authorPatrizia Farci
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
Search for more papers by this authorJens Bukh
Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre; and Department of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
Search for more papers by this authorHoward C. Thomas BSc, PhD, FRCP, FRCPath, FMedSci
Emeritus Professor of Hepatology, Department of Medicine, Imperial College London, London, UK
Search for more papers by this authorAnna S.F. Lok MD
Alice Lohrman Andrews Research Professor in Hepatology, Director of Clinical Hepatology, Professor of Internal Medicine, Associate Chair for Clinical Research, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA
Search for more papers by this authorStephen A. Locarnini MBBS, BSc(Hons), PhD, FRCPath
Head, Research & Molecular Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia
Search for more papers by this authorArie J. Zuckerman MD, DSc, FRCP, FRCPath, FMedSci
Emeritus Professor of Medical Microbiology, Formerly Principal and Dean, Royal Free Hospital School of Medicine
Search for more papers by this authorSummary
The chimpanzee model has played a major role both before and after the discovery of hepatitis C virus (HCV) as the etiologic agent of non-A, non-B hepatitis (NANBH). Chimpanzees were essential to prove that NANBH was indeed an infectious disease caused by a transmissible agent, and provided an in vivo system for the biological amplification of the putative virus to obtain sufficient material for attempts at identification. It was from a chronically infected chimpanzee that a large amount of plasma was obtained for the molecular cloning of the HCV genome. The chimpanzee model has played a critical role not only in the initial discovery but also in the post-HCV era. Studies in chimpanzees were instrumental to investigate the host immune response elicited by HCV and to determine the natural history of hepatitis C. Finally, chimpanzees remain the only animal model to study the immunogenicity and efficacy of vaccine candidates against HCV. In this chapter, we review the role that nonhuman primate models have played before and after the discovery of the etiologic agent of NANBH. Furthermore, we discuss the utility of small-animal models that have been developed over the past 10 years for studies of HCV.
References
- Purcell RH. Primates and hepatitis research. In: J Erwin, JC London, editors. Chimpanzee Conservation and Public Health: Environments for the Future. Rockville, MD: Diagnon Corporation/Bioqual, 1992; pp. 15–20.
- Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B hepatitis genome. Science 1989; 244: 359–362.
- Alter HJ, Purcell RH, Holland PV, Popper H. Transmissible agent in ‘non-A, non-B' hepatitis. Lancet 1978; 1: 459–463.
- Hollinger FB, Gitnick GL, Aach RD, et al. Non-A, non-B hepatitis transmission in chimpanzees: a project of the Transfusion-transmitted Viruses Study Group. Intervirology 1978; 10: 60–68.
- Tabor E, Gerety RJ, Drucker JA, et al. Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1978; 1: 463–466.
- Tabor E, April M, Seeff LB, et al. Acute non-A, non-B hepatitis: prolonged presence of the infectious agent in blood. Gastroenterology 1979; 76: 680–484.
- Feinstone SM, Mihalik KB, Karmimura T, et al. Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroform. Infect Immun 1983; 41: 816–821.
- Kuo G, Choo Q-L, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362–364.
- Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 1983; 85: 439–462.
- Tabor E. Development and application of the chimpanzee animal model for human non-A, non-B hepatitis. In: RJ Gerety, editor. Non-A, Non-B Hepatitis. New York: Academic Press, 1981; pp. 189–206.
- Tabor E, Purcell RH, Gerety RJ. Primate animal models and titered inocula for the study of human hepatitis A, hepatitis B, and non-A, non-B hepatitis. J Med Primatol 1983; 1: 305–318.
- Dienstag JL. Non-A, non-B hepatitis. II. Experimental transmission, putative virus agents and markers, and prevention. Gastroenterology 1983; 85: 743–768.
- Tabor E, Seeff LB, Gerety RJ. Chronic non-A, non-B hepatitis carrier state: transmissible agent documented in one patient over a six-year period. N Engl J Med 1980; 303: 139–143.
- Feinstone SM, Alter HJ, Dienes HP, et al. Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis 1981; 144: 588–598.
-
Ponzetto A,
Hoyer BH,
Popper H, et al.
Titration of the infectivity of hepatitis D virus in chimpanzees.
J Infect Dis
1987;
156:
72–78.
10.1093/infdis/155.1.72 Google Scholar
-
Tabor E,
Gerety RJ.
Inactivation of an agent of human non-A, non-B hepatitis by formalin.
J Infect Dis
1980;
142:
677–770.
10.1093/infdis/142.5.767 Google Scholar
- Yoshizawa H, Itoh Y, Iwarkiri S, et al. Non-A, non-B (type 1) hepatitis agent capable of inducing tubular ultrastructures in the hepatocyte cytoplasm of chimpanzees: inactivation of formalin and heat. Gastroenterology 1982; 82: 502–506.
- Purcell RH, Gerin JL, Popper H, et al. Hepatitis B virus, hepatitis non-A, non-B virus and hepatitis delta virus in lyophilized antihemophilic factor: relative sensitivity to heat. Hepatology 1985; 5: 1091–1099.
- Heinrich D, Kotitschke R, Berthold H. Clinical evaluation of the hepatitis safety of a α-propiolactone/ultraviolet treated factor IX concentrate (PPSB). Thromb Res 1982; 28: 75–83.
- He LF, Alling D, Popkin T, et al. Non-A, non-B hepatitis virus: determination of size by filtration. J Infect Dis 1987; 156: 636–640.
- Houghton M. Hepatitis C virus. In: BN Fields, DM Knipe, PM Howley, RH Chanock, editors. Fields Virology, 3rd ed. Philadelphia: Lippincott-Raven, 1996; pp. 1035–1058.
- Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494–1500.
- Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992; 327: 1899–1890.
- Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 2004; 39: 1469–1475.
- Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98–104.
- Abe K, Inchauspe G, Shikata T, Prince AM. Three different patterns of hepatitis C virus infection in chimpanzees. Hepatology 1992; 15: 690–695.
- Beach MJ, Meeks EL, Mimmas LT, et al. Temporal relationships of hepatitis C virus RNA and antibody responses following experimental infection of chimpanzees. J Med Virol 1992; 36: 226–237.
- Farci P, London WT, Wong DC, et al. The natural history of infection with hepatitis C virus (HCV) in chimpanzees: comparison of serologic responses measured with first- and second-generation assays and relationship to HCV viremia. J Infect Dis 1992; 165: 1006–1011.
- Shimizu YK, Weiner AJ, Rosenblatt J, et al. Early events in hepatitis C virus infection of chimpanzees. Proc Natl Acad Sci USA 1990; 87: 6441–6444.
- Major ME, Dahari H, Mihalik K, et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 2004; 39: 1708–1719.
- Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17–35.
- Purcell RH. Does non-A, non-B hepatitis cause hepatocellular carcinoma? Cancer Detect Prevent 1989; 14: 203–207.
- Kolykhalov AA, Agapov EV, Blight KJ, et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997; 277: 570–574.
- Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci USA 1997; 94: 8738–8743.
- Gottwein JM, Scheel TK, Callendret B, et al. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol 2010; 84: 5277–5293.
- Major ME, Mihalik K, Puig M, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 2002; 76: 6586–6595.
- Major ME, Mihalik K, Fernandez J, et al. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol 1999; 73: 3317–3325.
- Fernandez J, Taylor D, Morhardt DR, et al. Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. J Virol 2004; 78: 9782–9789.
- Callendret B, Bukh J, Eccleston HB, et al. Transmission of clonal hepatitis C virus genomes reveals the dominant but transitory role of CD8+ T cells in early viral evolution. J Virol 2011; 85: 11833–11845.
- Yanagi M, St Claire M, Emerson SU, et al. In vivo analysis of the 3′ untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci USA 1999; 96: 2291–2295.
- Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol 2000; 74: 2046–2051.
- Sakai A, Claire MS, Faulk K, et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci USA 2003; 100: 11646–11651.
- Forns X, Thimme R, Govindarajan S, et al. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci USA 2000; 97: 13318–13323.
- Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972–1974.
- Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110–113.
- Bukh J, Pietschmann T, Lohmann V, et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci USA 2002; 99: 14416–14421.
- Wright TL, Hsu H, Donegan E, et al. Hepatitis C virus not found in fulminant non-A, non-B hepatitis. Ann Intern Med 1991; 115: 111–112.
- Farci P, Alter HJ, Shimoda A, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996; 335: 631–634.
- Farci P, Munoz SJ, Shimoda A, et al. Experimental transmission of hepatitis C virus-associated fulminant hepatitis to a chimpanzee. J Infect Dis 1999; 179: 1007–1011.
- Sakai A, Takikawa S, Thimme R, et al. In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells. J Virol 2007; 81: 7208–7219.
- Bradley DW, Maynard JE, McCaustland KA. Non-A, non-B hepatitis in chimpanzees: interference with acute hepatitis A virus and chronic hepatitis B virus infections. J Med Virol 1983; 11: 207–213.
- Harrison TJ, Tsiquaye KN, Zuckerman AJ. Assay of HBV DNA in the plasma of HBV-carrier chimpanzees superinfected with non-A, non-B hepatitis. J Virol Methods 1983; 6: 295–302.
- Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135–140.
- Prince AM, Brotman B, Huima T. Immunity in hepatitis C infection. J Infect Dis 1992; 165: 438–443.
- Bassett SE, Guerra B, Brasky K, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001; 33: 1479–1487.
- Weiner AJ, Paliard X, Selby MJ, et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol 2001; 75: 7142–7148.
- Lanford RE, Guerra B, Chavez D, et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004; 78: 1575–1581.
- Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassemic children. Lancet 1994; 343: 388–390.
- Bukh J, Thimme R, Meunier JC, et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol 2008; 82: 8183–8195.
- Krawczynski K, Alter MJ, Tankersley DL, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996; 173: 822–828.
- Kao JH, Chen PJ, Lai MY, et al. Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. Gastroenterology 1992; 105: 583–587.
- Okamoto H, Mishiro S, Tokita H, et al. Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a. Hepatology 1994; 20: 1131–1136.
- Walker CM. Adaptive immunity to the hepatitis C virus. Adv Virus Res 2010; 78: 43–86.
- Farci P. New insights into the HCV quasispecies and compartmentalization. Semin Liver Dis 2011; 31: 356–374.
- Martell M, Esteban JL, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225–3229.
- Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633–642.
- Meunier JC, Engle RE, Faulk K, et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA 2005; 102: 4560–4565.
- Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 1998; 72: 3827–3836.
- Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623–626.
- Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791–796.
- Gottwein JM, Scheel TK, Jensen TB, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009; 49: 364–377.
- Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91: 7792–7796.
- Conrad ME, Lemon SM. Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin. J Infect Dis 1987; 156: 56–63.
- Knodell RG, Conrad ME, Ginsberg AL, Bell CJ. Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet 1976; 1: 557–561.
- Seeff LB, Zimmerman HJ, Wright EC, et al. A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study. Gastroenterology 1977; 72: 111–121.
- Yu MW, Mason BL, Guo ZP, et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995; 345: 1173–1174.
- Yu MY, Bartosch B, Zhang P, et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci USA 2004; 101: 7705–7710.
- Weiner AJ, Brauer MJ, Rosenblatt J, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180: 842–848.
- Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93: 15394–15399.
- Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339–344.
- Laskus T, Wilkinson J, Gallegos-Orozco JF, et al. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 2004; 127: 764–776.
- Bassett S, Thomas DL, Brasky KM, Lanford RE. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol 1999; 73: 1118–1126.
- Ray SC, Mao Q, Lanford RE, et al. Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. J Virol 2000; 74: 3058–3066.
- Institute of Medicine. Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity. Washington, DC: National Academies Press, 2011.
- Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927–933.
- Bissig KD, Wieland SF, Tran P, et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010; 120: 924–930.
- Meuleman P, Libbrecht L, De VR, et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005; 41: 847–856.
- Lindenbach BD, Meuleman P, Ploss A, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci USA 2006; 103: 3805–3809.
- Hiraga N, Imamura M, Tsuge M, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. FEBS Lett 2007; 581: 1983–1987.
- Bukh J, Meuleman P, Tellier R, et al. Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J Infect Dis 2010; 201: 1381–1389.
- Meuleman P, Bukh J, Verhoye L, et al. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 2011; 53: 755–762.
- Law M, Maruyama T, Lewis J, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008; 14: 25–27.
- Meuleman P, Catanese MT, Verhoye L, et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012; 55: 364–372.
- Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198–201.
- Hiraga N, Imamura M, Abe H, et al. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology 2011; 54: 781–788.
- Ohara E, Hiraga N, Imamura M, et al. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol 2011; 54: 872–878.
- Chayama K, Hayes CN, Hiraga N, et al. Animal model for study of human hepatitis viruses. J Gastroenterol Hepatol 2011; 26: 13–18.
- Walters KA, Joyce MA, Thompson JC, et al. Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response. PLoS Pathog 2006; 2: e59.
- Ilan E, Arazi J, Nussbaum O, et al. The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV. J Infect Dis 2002; 185: 153–161.
- Washburn ML, Bility MT, Zhang L, et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011; 140: 1334–1344.
- Amako Y, Tsukiyama-Kohara K, Katsume A, et al. Pathogenesis of hepatitis C virus infection in Tupaia belangeri. J Virol 2010; 84: 303–311.
- Wu GY, Konishi M, Walton CM, et al. A novel immunocompetent rat model of HCV infection and hepatitis. Gastroenterology 2005; 128: 1416–1423.
- Dorner M, Horwitz JA, Robbins JB, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011; 474: 208–211.
- Bukh J. Animal models for the study of hepatitis C virus infection and related liver disease. Gastroenterology 2012; 142: 1279–1287.